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S U M M A R Y
Background: There is disagreement regarding whether Lyme borreliosis is associated with adverse
pregnancy outcome.
Methods: We performed a review of the data from 95 women with Lyme borreliosis during pregnancy,
evaluated at the Center for Tick-borne Diseases, Budapest over the past 22 years.
Results: Treatment was administered parenterally to 66 (69.5%) women and orally to 19 (20%). Infection
remained untreated in 10 (10.5%) pregnancies. Adverse outcomes were seen in 8/66 (12.1%) parentally
treated women, 6/19 (31.6%) orally treated women, and 6/10 (60%) untreated women. In comparison to
patients treated with antibiotics, untreated women had a signiﬁcantly higher risk of adverse pregnancy
outcome (odds ratio (OR) 7.61, p = 0.004). While mothers treated orally had an increased chance (OR
3.35) of having an adverse outcome compared to those treated parenterally, this difference was not
statistically signiﬁcant (p = 0.052). Erythema migrans did not resolve by the end of the ﬁrst antibiotic
course in 17 patients. Adverse pregnancy outcome was more frequent among these ‘slow responder’
mothers (OR 2.69), but this was not statistically signiﬁcant (p = 0.1425) . Loss of the pregnancy (n = 7)
and cavernous hemangioma (n = 4) were the most prevalent adverse outcomes in our series. The other
complications were heterogeneous.
Conclusion: Our results indicate that an untreated maternal Borrelia burgdorferi s.l. infection may be
associatedwith an adverse outcome, although bacterial invasion of the fetus cannot be proven. It appears
that a speciﬁc syndrome representing ‘congenital Lyme borreliosis’ is unlikely.
 2009 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Lyme borreliosis is the most frequent vector-borne illness in
the temperate zone of the northern hemisphere. Early publica-
tions suggested that, like syphilis,maternal Borrelia burgdorferi s.l.
infection may seriously inﬂuence the outcome of pregnancy.
Stillbirth and congenital heart abnormalities have been
described.1–4 With the exception of some publications,5,6 most
early case reports have described patients with adverse outcomes
following their pregnancies. Incidence and cross-sectional studies
on populations of 1000–5000 pregnant women and/or their
offspring found hardly any cases of Lyme borreliosis and,
therefore, remained inconclusive with respect to risk for adverse
pregnancy outcome.7–11 Epidemiological evaluation of treated
and untreated patients is also complicated by the low rate of
untreated cases present and identiﬁed in most populations.12 In
the largest study to date on gestational Lyme borreliosis, almost
every patient was treated with ceftriaxone.4 Many years ago,* Corresponding author. Tel.: +36 30 9619134; fax: +36 1 3293898.
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patients had a much greater chance of suffering an adverse
outcome in pregnancy, but the number of patients was too low to
achieve meaningful results.13
The Center for Tick-borne Diseases, Budapest was opened in
1986 under the leadership of one of the authors (AL). Since then,
8149 erythema migrans (EM) patients have been seen, including
97 cases in which Borrelia burgdorferi s.l. infection was clinically
evident during pregnancy. Here we report our experience with
these cases.
2. Methods
2.1. Patients
From the 97 registered cases of gestational Lyme disease, we
were able to analyze 95. Twowomenwere lost to follow-up before
delivery. All women were seen by the same examiner (AL).
The following criteria for inclusion were used: (1) EM rash
during pregnancy, as deﬁned by the Centers for Disease Control
and Prevention (CDC)14 and the European Union Concerted Action
on Lyme Borreliosis (EUCALB)15 criteria (n = 72). (2) Patients wereses. Published by Elsevier Ltd. All rights reserved.
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commenced before or during pregnancy (n = 17); in many of them
the inﬂammation had already resolved at the time of the ﬁrst visit
to the center (n = 12). The condition for the inclusion of these latter
patients was a deﬁnitive description of the EMmade by the family
doctor or another institute. (3) Those with clinically diagnosed
acrodermatitis chronica atrophicans (ACA), with signs of inﬂam-
mation still present15 after delivery, which had commenced before
or during the pregnancy (n = 3) were included. (4) Patients with
facial palsy beginning during pregnancywith preceding EMorwith
the presence of intrathecal Borrelia antibody production16 (n = 3)
were also included.
In cases where a patient had Lyme borreliosis (EM) twice, and
both illnesses coincided with two separate pregnancies, only the
ﬁrst pregnancy was included. If a patient presented the active
clinical symptoms of late Lyme borreliosis (e.g., ACA) and during
this period of the untreated infection more pregnancies occurred,
only the ﬁrst pregnancy was included. Twin pregnancy only
concerned a single event. Seventy-nine offspring were examined
by one of the authors, a pediatrician who specializes in infectious
diseases (AL), and if not, a medical report registered by the family
pediatrician was also accepted.
The onset of the ﬁrst clinical symptom (starting point) and the
ﬁrst day of the antibiotic treatment (end point) were used to
calculate the length of the Borrelia infection during pregnancy.
Mothers were asked to report any later problem in their
offspring of suspected congenital origin.
2.2. Treatment
Some patients remained untreated (n = 10). At our center,
parenteral antibiotic treatment for pregnant woman with Lyme
borreliosis is preferred. While we initially used penicillin IV
2  10 MU (n = 9), ceftriaxone IV 2 g per day was used for the last
17 years (n = 57). The length of therapy for both antibiotics was
15 days. Oral treatment was applied in 19 patients; nine of them
visited our center after delivery. The other 10 mothers did not
show clinical evidence of an ongoing infection after a course of
oral treatment of at least 20 days had been concluded by the time
of the visit.
If EM had not resolved by the time an antibiotic course was
completed, then another antibiotic was prescribed. Further
antibiotics were prescribed for 17 women; these women were
considered ‘slow responders’.Table 1
Adverse outcomes in 20 pregnancies
Adverse outcome No. of
cases
Frequenc
(95% CI)
Spontaneous abortion 6 6.3 (2.4–
Stillbirth 1 1.1 (0.0–
Premature birth 1 1.1 (0.0–
Small for dates 1 1.1 (0.0–
Cavernous hemangioma 4 4.2 (1.2–
Neonatal jaundice requiring exchange transfusion 2a 2.1 (0.3–
Dysplasia coxae 2 2.1 (0.3–
Pyloric stenosis 1b 1.1 (0.0–
Papulovesicular eruption at birth 1 1.1 (0.0–
Cerebral bleeding 1 1.1 (0.0–
Muscular hypotonicity 1 1.1 (0.0–
Hypospadias 1c 1.1 (0.0–
Skeletal anomaly 1 1.1 (0.0–
CI, conﬁdence interval; NA, not available.
a One of these newborns also presented with dysplasia coxae.
b This newborn also had dysplasia coxae.
c This complication was accompanied by cavernous hemangioma.
d Data are for 1996–2006.20
e Data are for 1986–2006.21Since some patientswere treatedwithmore than one antibiotic,
if any of these were parenterally administered, then the patient
was considered as a case of parenteral treatment for the statistical
evaluation.
2.3. Serology
Every mother and 85 offspring were tested for Lyme borreliosis
at the time of the ﬁrst visit, with a homemade immunoblot using
Borrelia afzelii (ACA1) as an antigen.17 The speciﬁcity of our test
was 99% in infants, 97% in healthy blood donors, and 92% in
‘problem samples’. The sensitivity of the test was 48% in EM, 75% in
lymphocytic meningoradiculitis, and 100% in the ACA and arthritis
group.18
2.4. Statistics
The statistical analyses were performed using R statistical
software.19 Fisher’s exact test was used for the comparison of
proportions. The association of the outcomes and treatment type
was quantiﬁed by logistic regression. The p-values are two-
tailed.
3. Results
We registered 23 adverse outcomes in 20 (21.1%) of the 95
offspring; these are listed in Table 1. The frequency of cavernous
hemangiomawas higher in our study population than expected, as
compared to the average frequency in Hungary.20,21 Three of the
four patients with the adverse outcome of hemangioma were
treated parenterally and one remained untreated. The latter
patient presented with a single hemangioma of the skin
complicated with hypospadias. Another offspring of a treated
(slow responder) mother showed multiple hemangiomas of the
skin. The third patient presented with a nevus ﬂammeus covering
almost half of the face. The fourth patient had multiple skin
hemangiomas complicated with liver hemangiomas detected by
ultrasound examination. In our series, dysplasia coxae was also
more frequent than the average incidence in Hungary. Both
mothers having children with this outcome were treated with IV
ceftriaxone and one of them was a slow responder. Another slow
responder mother delivered a newborn whose left fore-foot was
shorter by 2 cm than the right at birth. An X-ray examination later
showed that half of the L 5 vertebra was missing .y, % Start of infection in
pregnancy weeks (average)
Average incidence
in Hungary, % (95% CI)19,20
13.2) 1–5 (2) 14.8 (14.1–15.6)d
5.7) 5 0.51 (0.48–0.55)d
5.7) 17 8.2–9.8e
5.7) 13 NA
10.4) 13–27 (21) 0.11 (0.08–0.14)e
7.4) 13–38 (25) NA
7.4) 18; before conception 0.21 (0.15–0.27)e
5.7) Before conception 0.02 (0.02–0.03)e
5.7) 38 NA
5.7) 4 NA
5.7) 4 NA
5.7) 27 0.21 (0.20–0.23)e
5.7) 13 NA
Table 2
Association between the treatment and pregnancy outcome in maternal Lyme borreliosis
Adverse
outcome
Healthy
newborn
OR (95% CI) P
Untreated/treated 6/14 4/17 7.61 (1.90–30.51) 0.00419
Untreated/orally treated 6/6 4/13 3.25 (0.66–15.98) 0.14691
Untreated/parenterally treated 6/8 4/58 10.87 (2.51–47.08) 0.00141
Orally/parenterally treated 6/8 13/58 3.35 (0.99–11.31) 0.0518
OR, odds ratio; CI, conﬁdence interval.
Table 3
Pregnancy outcome and clinical symptoms of Lyme borreliosis analyzed separately
with regard to the time of the initial visit
Pregnancy
loss
Other adverse
outcome
Healthy
neonate
Total
All patients (N=95)
Therapy p=0.001
No 3 (30%) 3 (30%) 4 (40%) 10
Oral 3 (15.8%) 3 (15.8%) 13 (68.4%) 19
Parenteral 1 (1.5%) 7 (10.6%) 58 (87.9%) 66
Clinical symptom p=1
ACA 0 (0%) 0 (0%) 3 (100%) 3
EM 7 (7.9%) 13 (14.6%) 69 (77.5%) 89
FP 0 (0%) 0 (0%) 3 (100%) 3
Patients visiting during pregnancy (n=75)
Therapy p=0.001
No 1 (100%) 0 (0%) 0 (0%) 1
Oral 3 (30%) 1 (10%) 6 (60%) 10
Parenteral 1 (1.6%) 7 (10.9%) 56 (87.5%) 64
Clinical symptom p=1
ACA 0 (0%) 0 (0%) 0 (0%) 0
EM 5 (6.9%) 8 (11.1%) 59 (81.9%) 72
FP 0 (0%) 0 (0%) 3 (100%) 3
Patients visiting after delivery (n=20)
Therapy p=0.531
No 2 (22.2%) 3 (33.3%) 4 (44.4%) 9
Oral 0 (0%) 2 (22.2%) 7 (77.8%) 9
Parenteral 0 (0%) 0 (0%) 2 (100%) 2
Clinical symptom p=0.657
ACA 0 (0%) 0 (0.0%) 3 (100%) 3
EM 2 (11.8%) 5 (29.4%) 10 (58.8%) 17
FP 0 (0%) 0 (0%) 0 (0%) 0
ACA, acrodermatitis chronica atrophicans; EM, erythema migrans; FP, facial palsy.
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the average in Hungary. Other complications either did not differ
statistically or the low number of cases did not permit statistical
calculation (Table 1). We saw one untreated patient whose
pregnancy resulted in stillbirth at 5 months of gestation. Her ﬁrst
visitwas four days later, when a 30 cmEMrashwas still visible. Two
cases of neonatal jaundice requiring exchange transfusion were
observed. One of the mothers was treated with 4  125 mg
erythromycin for 30 days but her EM persisted for another 30 days
after completion of this treatment (slow responder). This mother
visited our center only after delivery. The other mother received
ceftriaxone treatment.We sawonenewbornwith a papulovesicular
dermatitis, which persisted for 1month. Hismother ﬁrst visited the
center 2weeks following delivery. Theuntreatedmother still had an
EMrash at that time. In anotherwoman,whovisitedour center after
delivery, EMwas treated with erythromycin 4  125 mg for 8 days,
but it persisted for a further 36 days following completion (slow
responder). Her newborn suffered cerebral bleeding. Mental and
physical developmentwas delayed. Pyloric stenosis developed in an
infant born to a mother treated with ceftriaxone. This case was
complicatedwithdysplasia coxae. Onenewbornwas delivered at 35
weeks of gestation; her mother was treated with oral cefuroxime.
Another newborn was small for dates (2200 g at 39 weeks). Her
mother was treated with ceftriaxone.
Adverse outcomes were seen in 8/66 (12.1%) women treated
parenterally, 6/19 (31.6%) women treated orally, and 6/10 (60.0%)
untreated women. Untreated patients had a higher likelihood of an
adverse pregnancy outcome when compared with treated patients
(Table 2). Slow responders (n = 17) showed higher chance (OR 2.69)
to have an adverse outcome (n = 5, 29.4%) than the normal
responders (n = 68 with 9 adverse outcomes, 13.2%) but it was not
statistically signiﬁcant (p = 0.1425). While mothers treated orally
had an increased chance of adverse outcome compared to those
treated parenterally, this difference was not statistically signiﬁcant.
Six of the 20 women with adverse outcomes had not been
treated. The most frequent reasons for this were that patients had
not paid attention to their symptoms or that the family doctors or
obstetricians had not recognized the EM. Four of the 10
pregnancies in mothers who remained untreated resulted in a
favorable outcome. The infection in three of these mothers with
ACA had started years before the conception and had remained
unrecognized and untreated during thewhole period of pregnancy.
Their acrodermatitis was still inﬂamed at the ﬁrst visit following
delivery, indicating that the infection was still active at that time.
One patient was worried about the antibiotic treatment and
therefore rejected it. She lost her fetus 56 days later in week 13 of
pregnancy.
A smaller (postnatal presentation) group (n = 20 (21.1%), 3 ACA
and 17 EM) ﬁrst visited our center after delivery; eight of these
patients presented with clinical signs of active Borrelia infection.
The inﬂammation had already resolved at the ﬁrst visit in the
remaining 12, but these patients had a deﬁnitive description of the
EM made by the family doctor or another institute.
Adverse birth outcome was more frequent (7/20 (35%)) in the
postnatal presentation group compared to those seen during their
pregnancy (13/75 pregnancies (17.3%)), but this difference was notstatistically signiﬁcant (odds ratio (OR) 2.01, 95% conﬁdence
interval 0.60–6.32, p = 0.24). We analyzed the data for the prenatal
and postnatal presentation groups separately, due to the potential
for bias (Table 3).
The interval over which the mother was infected during
pregnancy varied widely (0–280 days, average 33.01 days,
standard deviation (SD) 54.59 days). We observed no relationship
between the length of infection during pregnancy and adverse
pregnancy outcome (OR 1.00, p = 0.953).
There was no statistically signiﬁcant difference in the general
state of health between the treated and untreated mothers. All
untreated mothers with an adverse pregnancy outcome were
regularly checked by their obstetricians. Only one of the mothers
withspontaneousabortionhadahistoryofasimilarepisode.Noneof
the patients used illicit drugs, smoked cigarettes, or regularly drank
alcohol during their pregnancies. All were Caucasian. The average
age of thewomenwas 29.7 (SD4.3) years. Forty-ﬁve (47.4%)women
had auniversitydegree. Fifty-ninemothers (62.1%) recognizeda tick
bite and 49 (51.6%) were serologically positive for Borrelia antibody
at the ﬁrst visit to our center. All ACApatients revealed an extremely
strong reaction in Borrelia immunoblot. The age and educational
statusof thewomen, serological results, and recognitionofa tickbite
were not correlated with pregnancy outcome.
Pregnancy loss most often occurred when the infection was
acquired in the ﬁrst weeks of pregnancy. Five of the pregnancy
Table 4
Pregnancy outcome as a function of the time of appearance of Lyme borreliosis
Pregnancy outcome Start of infection before
pregnancy (No. of patients)
Trimester in which the infection started during
pregnancy, No. of patients
Total
I II III
Pregnancy loss 1 5 1 0 7
Other adverse outcome 1 1 7 4 13
Healthy newborn 7 24 21 23 75
Total 9 30 29 27 95
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week; one stillbirth (at 22 weeks) occurred amongst our patients
(Table 4). We have no information regarding any morphological
exams done on these pregnancy losses.
Our patients come to us from all over Hungary. There was no
opportunity for PCR or culture attempts on the placentas or on the
fetuses. Borrelia immunoblot from the cord blood was performed
for 74 patients, including seven caseswith adverse outcomes. None
of the tested newborns showed an IgM reaction. Moreover, we
were unable to detect Borrelia burgdorferi IgM antibodies in any of
the six infants with congenital anomalies (four of them were born
tomothers infected in late pregnancy) or in 17 healthy infants who
were tested weeks or months after delivery. All newborns born to
mothers who were IgG-positive at delivery were IgG-positive. The
IgG reaction of the newborns mirrored the immunoblot pattern of
their mothers, suggesting that these antibodies were of maternal
origin.
4. Discussion
We see 60–80% of the reported cases of Lyme borreliosis in
Hungary at our center, and probably a higher rate of pregnant
women with Borrelia infection. Most of our patients were referred
by their family doctors, obstetricians, dermatologists, or physicians
working in infectious diseases departments.
Our ﬁndings demonstrate a statistically signiﬁcant association
between untreated Lyme borreliosis and adverse pregnancy
outcome. The association is also supported by the fact that a
similar, though statistically non-signiﬁcant, trend was found with
slow responder mothers (those whose EM had not resolved by the
time of ﬁrst course antibiotic completion) and adverse outcomes.
Many controversial papers have been published asserting a range
of effects, from serious to no adverse effects, on the offspring in
maternal Lyme borreliosis. We think that our study is sufﬁciently
heterogeneous and with a large number of mothers gathered for
statistical evaluation.
Observational, retrospective studies have an inherent risk of
bias in collecting and selecting patients. EM is a typical early sign of
Lyme borreliosis, while ACA is a typical late form of Borrelia
infection in Europe. Both dermatological involvements have
characteristic inﬂammation, which usually rapidly disappears
during or shortly after treatment. In our study, in cases that
remained untreated, the patient’s clinical symptoms were clearly
described by other doctors or were still evident and diagnostic (i.e.,
EM or ACA) at the time of their ﬁrst visit to our center.
It may be possible that a selection bias exists in this study, as
women who had an adverse birth outcome may have been more
likely to seek help at the clinic after delivering a baby. For obvious
reasons, most of the untreated women (all but one, who ultimately
rejected all treatment options) visited our center only after
delivery. The association between the untreated Lyme borreliosis
and ﬁrst visit only after delivery was expected.
We could see no other differences than the application of
antibiotic treatment in women with adverse pregnancy outcomes
and those with healthy offspring, but we cannot rule out that other
factors present might have inﬂuenced neonatal outcome. Weshould stress that adverse pregnancy outcome is a combination of
several perinatal and neonatal indicators with different degrees of
severity.
It appears that a speciﬁc syndrome representing ‘congenital
Lyme borreliosis’ is unlikely. However, spontaneous abortion,
stillbirth, and preterm birth have frequently been identiﬁed in
other published studies1,2,4 and were also found in our series. The
miscarriage rate in our cohort is much lower than the average in
Hungary. Pregnancy loss was signiﬁcantly more frequent among
untreated patients than among the parenterally treated women in
our study population. We frequently observed hemangioma, a
hitherto unpublished symptom coincidental with maternal
Borrelia infection. In contrast, cardiac abnormalities were not
found; these have been the most frequently published conse-
quence of maternal Lyme borreliosis in other reports.3,7,8,22 We
found some of the symptoms mentioned in other papers, such as
hyperbilirubinemia,23 cerebral bleeding,24 generalized rash,2 and
congenital urologic malformations.4,7 One of the infants in the
present study had pyloric stenosis, and Strobino et al.7 have
described a newborn with gastric reﬂux.
It is striking that of the three pregnancieswhere themothers had
late Lyme borreliosis (i.e., ACA) and in which the infection was
acquired longbefore conception and remaineduntreatedbefore and
during the whole period of pregnancy, none resulted in any fetal or
newborn harm. This observation is consonant with an animal study
whereBorrelia infectiondidnot result in fetal deathwhenmicewere
challenged weeks before mating in comparison with 12% fetal
deaths when the infection was introduced after mating.25 Patients
with late Lyme borreliosis, especially with ACA, always produce a
strong antibody reaction against B. burgdorferi, while most EM
patients usually have faint antibody titers.18 The intensive immune
response of ACA patients may play a role in preventing Borrelia
spread and transmission to the placenta or fetus.
Placentas and offspring were not tested for Borrelia by PCR or
culture in our study. Therefore, it cannot be concluded that the
adverse outcomeswere a result of a Borrelia invasion of the fetus or
placenta. The adverse outcome may have been a consequence of
damage to the placenta or a maternal reaction to the infection.
There are animal studies that have demonstrated maternal–fetal
transmission,26 but others have not supported this conclusion.25
At our center we prefer parenteral antibiotic treatment for
Lyme borreliosis during pregnancy, due to suggestions in some
papers that oral penicillin treatment is coincidental with
intrauterine embryonic, fetal, or newborn death.2,24 During the
last 17 years, intravenous ceftriaxone has been preferred to
treatment with oral amoxicillin in our practice. This is due to the
pharmacokinetics of amoxicillin as compared to ceftriaxone.
According to Andrew et al.,27 amoxicillin has lower plasma
concentrations and more rapid elimination during pregnancy than
in the postpartum or non-pregnant situation. The pharmacoki-
netics of ceftriaxone, however, are not signiﬁcantly inﬂuenced by
pregnancy28. In addition, ceftriaxone in vitro is more effective
against Borrelia than other b-lactams.29,30
Our present data do not conclusively support the superiority of
high dose IV penicillin or parenterally administered ceftriaxone
over the oral antibiotic treatment, since we could not show a
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were unable to examine the placenta or fetus for direct Borrelia
invasion in the cases of pregnancy loss, therefore the causal
relationship remains undecided in spite of the statistical associa-
tion. Similarly, we could not ﬁnd an IgM antibody reaction in the
offspring in the other cases of adverse pregnancy outcome,
therefore our data suggest that these heterogeneous symptoms
of newborns are not related to Borrelia invasion of the fetus.
Ideally, a prospective, multicenter study should be conducted,
enrolling sufﬁcient numbers of women, in order to adequately
address these research questions.
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